Mithra Submits Myring™ for European Marketing Approval

  • Myring™ regulatory approvals in Europe and the US expected in 2018
  • Regulatory submission follows recent European GMP approval for Myring™ production at Mithra CDMO

Liège, Belgium, 17 July 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces that it has filed Myring™ for marketing approval in Europe. Myring™ is Mithra’s version of Nuvaring™, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA). The global market for Nuvaring™ amounts to approximately USD 960 million, with over 75% of sales in the US.

Mithra Strengthens E4 Patent Position in Australian Market

  • Patents granted for Estetrol (E4) synthesis protect manufacturing process until 2032
  • Certificate of grant covers E4’s use alone as an emergency contraceptive

Liège, Belgium, 6 July 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that the Australian Patent Office, IP Australia, has granted patents covering the synthesis process of Estetrol (E4). IP Australia has also accepted a patent application for a patent covering E4 alone as an emergency contraceptive. E4, a naturally ocurring estrogen, is currently being studied in the E4 Freedom Phase III study program in contraception (Estelle®, 15 mg E4/3 mg drospirenone) and in the E4 Relief Phase II trial for menopause (Donesta®, dose-finding study with E4 alone).